Loading clinical trials...
Loading clinical trials...
An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Conditions
Interventions
QR-110
Locations
3
United States
University of Iowa
Iowa City, Iowa, United States
Scheie Eye Institute, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Ghent University Hospital and Ghent University
Ghent, Belgium
Start Date
May 13, 2019
Primary Completion Date
October 3, 2022
Completion Date
October 3, 2022
Last Updated
October 15, 2024
NCT07134777
NCT06070467
NCT06451172
NCT07529041
NCT06117332
NCT06364605
Lead Sponsor
Laboratoires Thea
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions